Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905404 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL16905405 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL16905403 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL16964987 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL16905402 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL22766836 | 0.82 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL4197547 | 0.80 | CA12 (0.31) | CA12CA1CA2CA9RECQL | |
| SCHEMBL3936173 | 0.80 | CA12 (0.31) | CA12CA1CA2CA9RECQL | |
| SCHEMBL5781735 | 0.80 | CA12 (0.31) | CA12CA1CA2CA9RECQL | |
| SCHEMBL3943817 | 0.78 | CA12 (0.31) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | SMN1; SMN2 4496/4885CA12 4244/4885CA1 4802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.